PDCD1 and non-small cell lung carcinoma: Indeed, there are some ongoing clinical trials (KEYNOTE‐789, CheckMate722) comparing the efficacy of anti‐PD‐1/PD‐L1 inhibitors plus chemotherapy with chemotherapy alone in NSCLC patients after progression on TKI treatment, including those treated with osimertinib.